Both the direct inhibition of PCIF1 expression through siRNA therapy and the inhibition of PCIF1 methyltransferase activity through structurally designed small molecule compounds suggest new possibilities to improve therapeutic strategies for patients with cancer. The gene discussed is PCIF1; the disease is cancer.